PMID: 9448900Aug 1, 1997Paper

Central control mechanisms in hypertension

Australian and New Zealand Journal of Medicine
L ArnoldaJ P Chalmers

Abstract

There is substantial evidence for an activation of the sympathetic nervous system in man as well as in genetic models of hypertension, such as the spontaneously hypertensive rat (SHR), but we are only beginning to understand the central mechanisms that generate changes in sympathetic activity and elevate blood pressure (BP). Significant recent advances have been made in defining the neural pathways involved in BP regulation and in identifying the neurotransmitters these neurones utilise. In this overview, we describe the neural pathways within the medulla oblongata and spinal cord that participate in BP control and examine the role of amino acid neurotransmitters within these pathways. We demonstrate how alterations in these pathways explain the sympathetic activation observed in the SHR and contribute to hypertension in this model. Lastly, we examine the application of modern molecular biological approaches to further our understanding of the neural regulation of the circulation. In these studies, we used the administration of antisense oligonucleotides to interrupt gene expression.

References

Sep 1, 1975·The Journal of Physiology·J LipskiK M Spyer
Jan 1, 1988·Annual Review of Physiology·R B McCall
Jan 1, 1980·Annals of Internal Medicine·J Lowenstein
Mar 1, 1995·Blood Pressure·A P SchroederO L Pedersen
Jan 1, 1995·Clinical and Experimental Hypertension : CHE·I J Llewellyn-SmithJ P Chalmers
May 1, 1994·British Journal of Obstetrics and Gynaecology·S Paterson-BrownM de Swiet
Apr 1, 1993·Baillière's Clinical Endocrinology and Metabolism·M D Esler
Oct 1, 1955·Circulation·A E DOYLE, F H SMIRK
Sep 19, 1964·British Medical Journal·B N PRICHARD, P M GILLAM
May 1, 1946·Journal of Neurophysiology·R S ALEXANDER

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.